Among the following dopamine agonists used in Parkinson's disease, which is the most commonly prescribed agent as monotherapy in early-stage disease in current clinical practice?

Explanation

## Most Commonly Prescribed Dopamine Agonist in Early Parkinson's Disease ### Pramipexole — The Preferred Early-Stage Agent **Key Point:** Pramipexole and ropinirole are the non-ergot dopamine agonists of choice in modern practice. Pramipexole is statistically the most frequently prescribed, particularly for early-stage monotherapy. ### Why Pramipexole Over Other Agonists? | Feature | Pramipexole | Ropinirole | Bromocriptine | Apomorphine | |---|---|---|---|---| | **Drug class** | Non-ergot | Non-ergot | Ergot-derived | Ergot-derived | | **Cardiac safety** | Excellent | Excellent | Risk of valvular disease | Risk of valvular disease | | **Pulmonary fibrosis risk** | No | No | Yes | Yes | | **Dosing frequency** | TDS (or extended-release) | TDS (or extended-release) | BD-TDS | SC injection | | **Early monotherapy use** | ✓ Very common | ✓ Common | ✗ Avoided | ✗ Rescue only | | **Cost in India** | Moderate | Moderate | Low (older) | High (injection) | **High-Yield:** Ergot-derived agonists (bromocriptine, apomorphine) are **avoided in early-stage monotherapy** due to: - Cardiac valvulopathy (5–30% risk with long-term use) - Pulmonary fibrosis - Retroperitoneal fibrosis - Pleural thickening ### Clinical Pearl: Current Treatment Paradigm In early Parkinson's disease (≤5 years, age <70 years), the choice is between: 1. **Dopamine agonist monotherapy** (pramipexole or ropinirole preferred) — delays motor complications 2. **Levodopa monotherapy** — faster symptom control but earlier dyskinesias Pramipexole is preferred because: - Non-ergot (no fibrotic complications) - Excellent tolerability - Extended-release formulation available (once daily) - Neuroprotective properties (theoretical, in animal models) ### Why Not the Other Options? **Bromocriptine:** - Ergot-derived; carries risk of valvular disease and pulmonary fibrosis - Largely superseded by non-ergot agonists - Still used in some resource-limited settings due to lower cost - NOT the most common choice in current practice **Ropinirole:** - Equally effective non-ergot agonist - Used as frequently as pramipexole in some centres - Slightly less commonly prescribed than pramipexole in epidemiological surveys **Apomorphine:** - Subcutaneous or sublingual injection/infusion - Reserved for **advanced disease with motor fluctuations** - Not used for early-stage monotherapy - Requires antiemetic prophylaxis (domperidone) **Mnemonic:** **PRAM** = **P**ramipexole/Ropinirole = **A**gents of choice (non-ergot); **M**odern, safe. Avoid **B**romocriptine (ergot-**B**ad fibrosis) and **A**pomorphine (**A**dvanced disease only). ### Epidemiological Note In large Parkinson's disease registries and real-world practice surveys (Europe, USA, India), pramipexole and ropinirole together account for >70% of dopamine agonist prescriptions in early disease, with pramipexole slightly ahead.